Shares in Spire Healthcare surged to the top of the FTSE 250 on Wednesday after the company’s board signaled its willingness to back a £1 billion takeover approach from one of its largest shareholders. The move underscores a growing appetite for private medical infrastructure as systemic pressures on the United Kingdom’s public health system drive patients toward self-funded care.
The bid comes from Toscafund, a London-based private equity firm and Spire’s second-biggest existing investor. Toscafund has proposed an offer of 250p per share, representing a 66 per cent premium over Wednesday’s closing price of 150.4p. The market responded immediately, with Spire Healthcare shares rocket after £1bn bid approach, climbing 45 per cent to 218p as investors bet on the deal’s completion.
While Spire noted that discussions remain at a “relatively early stage,” the board stated it “would be minded to recommend unanimously” the 250p offer to shareholders. This openness marks a shift in tone from previous leadership stances, as the board had previously seen other offers fall short of its valuation requirements.
The Strategic Drive Behind the Bid
The timing of the approach reflects a broader structural shift in the UK healthcare landscape. As the National Health Service (NHS) continues to struggle with historic waiting lists, an increasing number of patients are opting for private alternatives to avoid prolonged delays for elective surgeries.
Spire is uniquely positioned to capture this demand. Operating 38 hospitals and more than 60 clinics across England and Wales, the company has established itself as the UK’s leading private provider of hip and knee replacements by volume. Beyond individual patient care, the firm also manages workplace health services for approximately 1,400 employers, diversifying its revenue streams.
In a separate trading update released Wednesday, Spire reported that while revenue from its NHS partnerships remained “as expected,” growth in private patient revenue—particularly from “self-pay” individuals—has continued to accelerate. This trend suggests that the “middle market” of UK patients is increasingly willing to pay out-of-pocket for faster access to specialist care.
Financial Transformation and Profitability
The bid arrives as Spire navigates a complex financial transition. For the 2025 fiscal year, the company reported annual revenue of £1.6 billion, a 4.5 per cent increase. However, profit before tax fell by more than 50 per cent to £18.6 million.
Management has characterized this dip not as a failure of demand, but as a deliberate “year of transformation.” The company has spent the last twelve months centralizing its administration into patient support centres and lowering the overall cost of delivery. From an analyst’s perspective, this suggests a business that has prioritized long-term operational efficiency over short-term earnings—making it a more attractive target for a private equity firm like Toscafund that specializes in operational restructuring.
| Metric (2025) | Value | Change |
|---|---|---|
| Annual Revenue | £1.6 billion | +4.5% |
| Profit Before Tax | £18.6 million | -50%+ |
| Patient Volume | 1.4 million | N/A |
A History of Failed Suitors
Toscafund is no stranger to high-stakes corporate maneuvers, having previously collaborated with Penta Capital to take the telecoms provider TalkTalk private in 2020. However, Spire has proven to be a hard target to secure. In 2021, the company rejected a 250p per share bid from Australia’s Ramsay Healthcare.
More recently, Spire confirmed in January that it had engaged in talks with other private equity heavyweights, including Bridgepoint and Triton. None of those discussions resulted in a formal offer, leaving the door open for Toscafund to step in as the preferred suitor.
Some City experts believe the current 250p offer may be a floor rather than a ceiling. Miles Dixon, an analyst at Peel Hunt, suggested that the intrinsic value of the business may exceed 250p, noting that the UK landscape for private care is moving in only one direction. However, Dixon also cautioned that “fatigue around offers” could play a role, noting that since the bidder is already a major shareholder, a deal at the current proposed price is highly probable.
What Happens Next
The deal now enters a strict regulatory window. Under the UK City Code on Takeovers and Mergers, Toscafund has until 5pm on June 11 to submit a firm, binding offer. If the fund fails to do so, it will be barred from making another bid for the company for six months.
Should the offer materialize and receive board approval, the focus will shift to the shareholders, who must decide if the 66 per cent premium sufficiently compensates them for the loss of a public listing in a sector seeing unprecedented demand.
Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice.
We invite readers to share their thoughts on the privatization of healthcare infrastructure in the comments below.
